文献速递泌尿生殖与妇科肿瘤放疗

宫颈癌扩大野IMRT同步化疗:急性胃肠毒性剂量体积约束

Dose-volume constraints for severe acute gastrointestinal toxicity in cervical cancer patients receiving extended-field intensity-modulated radiotherapy and concurrent chemotherapy.
PubMed 文献 · Radiother Oncol · 2025-02-04

该研究分析273例接受扩大野调强放疗同步化疗的宫颈癌患者十二指肠和小肠袢剂量学数据,发现十二指肠V29和V49可预测≥3级呕吐,小肠袢V22可预测≥3级腹泻。限制上述剂量体积参数可能有助于降低急性≥3级胃肠毒性风险。

要点

  • 十二指肠V29>43.5%者≥3级呕吐发生率12.8%,V29≤43.5%者为1.3%(p=0.008)。
  • 小肠袢V22>62.3%者≥3级腹泻发生率5.6%,V22≤62.3%者为0.6%(p=0.031)。
  • 十二指肠V29>51.3%者因呕吐改计划发生率17.6%,V29≤51.3%者为3.3%(p<0.001)。

核心结论

  • 限制十二指肠V29和V49以及小肠袢V22可能有助于降低宫颈癌扩大野同步IMRT治疗中急性≥3级胃肠毒性风险。

研究设计与样本

  • 研究分析了273例 eligible 宫颈癌患者的十二指肠和小肠袢剂量学数据,采用逻辑回归和Pearson两两相关识别最佳预测因子,用受试者工作特征曲线确定最佳截断值,并建立逻辑模型预测正常组织并发症概率。

主要发现

  • 26例患者发生≥3级呕吐,7例发生≥3级腹泻。
  • 十二指肠V29(p=0.002)或V49(p=0.014)均可预测≥3级呕吐发生率。
  • 十二指肠V29≤43.5% vs >43.5%者≥3级呕吐发生率为1.3% vs 12.8%(p=0.008)。
  • 十二指肠V49≤9.2% vs >9.2%者≥3级呕吐发生率为7.6% vs 16.1%(p=0.077)。
  • 22例患者因呕吐需修改计划;十二指肠V29(p=0.012)为再计划预测因子,V29≤51.3% vs >51.3%者再计划发生率为3.3% vs 17.6%(p<0.001)。

关键数值与推荐

  • 十二指肠V29≤43.5% vs >43.5%:≥3级呕吐发生率1.3% vs 12.8%(p=0.008)。
  • 十二指肠V49≤9.2% vs >9.2%:≥3级呕吐发生率7.6% vs 16.1%(p=0.077)。
  • 十二指肠V29≤51.3% vs >51.3%:因呕吐再计划发生率3.3% vs 17.6%(p<0.001)。
  • 小肠袢V22≤62.3% vs >62.3%:≥3级腹泻发生率0.6% vs 5.6%(p=0.031)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Extended-field intensity-modulated radiotherapy (IMRT) and concurrent chemotherapy may lead to severe toxicity. This study aims to investigate the incidence and dosimetric predictors of acute gastrointestinal toxicity in cervical cancer patients. METHODS AND MATERIALS: Dosimetric data of the duodenum and small bowel loop from 273 eligible patients were analyzed. Logistic regression and Pearson's pairwise correlation were used to identify the best predictors. Receiver operating characteristic curves were used to determine the optimal cutoff values. Logistic models were established to predict the normal tissue complication probability. RESULTS: Twenty-six patients experienced grades ≥ 3 (G3+) vomiting, while seven experienced G3+ diarrhea. Either the duodenal volume receiving ≥ 29 Gy (V29; p = 0.002) or V49 (p = 0.014) could predict the incidence of G3+ vomiting. The incidence was 1.3 % vs. 12.8 % in patients with V29 ≤ 43.5 % vs. > 43.5 % (p = 0.008). For patients with V49 ≤ 9.2 % vs. > 9.2 %, the incidence was 7.6 % vs. 16.1 % (p = 0.077). The plans for 22 patients had to be modified due to vomiting. It was found that duodenal V29 (p = 0.012) was a predictor for replanning, with an incidence of 3.3 % vs. 17.6 % in patients with V29 ≤ 51.3 % vs. > 51.3 % (p < 0.001). The V22 of the small bowel was selected to predict the incidence of G3+ diarrhea, which were 0.6 % and 5.6 % in patients with V22 ≤ 62.3 % and > 62.3 %, respectively (p = 0.031). CONCLUSION: Limiting V29 and V49 of the duodenum, as well as V22 of the small bowel loop, may help reduce the risk of acute G3+ gastrointestinal toxicity when treating cervical cancer with extended-field concurrent IMRT.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Gao H, Wu H, Zhang Y, et al. Dose-volume constraints for severe acute gastrointestinal toxicity in cervical cancer patients receiving extended-field intensity-modulated radiotherapy and concurrent chemotherapy. Radiother Oncol. 2025. PMID: 39914743. doi:10.1016/j.radonc.2025.110777

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。